BioCentury
ARTICLE | Financial News

Integrated Diagnostics secures $47.3 million

April 30, 2014 12:43 AM UTC

Integrated Diagnostics Inc. (Seattle, Wash.) secured $47.3 million on Tuesday through a combination of equity and debt. The company raised $30.3 million in a series B round led by new investor Baird Capital. Existing investors InterWest Partners and the Wellcome Trust also participated, along with new investor Alexandria Venture Investments. Integrated Diagnostics also secured $17 million in debt financing from Life Sciences Alternative Funding. Baird Capital's Michael Liang will join Integrated Diagnostics' board.

Integrated Diagnostics markets its Xpresys Lung non-invasive blood test to help physicians identify lung nodules likely to be benign. The test, which is available through Integrated Diagnostics' CLIA-certified laboratory, measures the relative abundance of proteins from multiple lung cancer disease pathways using multiple reaction monitoring mass spectroscopy. ...